Acyclovir Dosing for Chickenpox
For chickenpox treatment, use oral acyclovir 800 mg four times daily for 5 days in adults and children over 40 kg, or 20 mg/kg four times daily (maximum 800 mg per dose) for 5 days in children 2 years and older weighing ≤40 kg, initiated within 24 hours of rash onset. 1
Oral Acyclovir Dosing
Standard Dosing (FDA-Approved)
- Children ≥2 years and ≤40 kg: 20 mg/kg per dose orally 4 times daily (80 mg/kg/day) for 5 days 1
- Adults and children >40 kg: 800 mg orally 4 times daily for 5 days 1
Critical timing: Treatment must be initiated within 24 hours of rash onset for optimal benefit 2. The evidence consistently demonstrates that acyclovir reduces duration of fever, number of new lesions, and severity of symptoms when given early 2, 3, 4.
Renal Dose Adjustments for Oral Therapy (800 mg regimen)
- CrCl >25 mL/min: 800 mg every 4 hours, 5 times daily
- CrCl 10-25 mL/min: 800 mg every 8 hours
- CrCl 0-10 mL/min: 800 mg every 12 hours
- Hemodialysis patients: Administer additional dose after each dialysis session 1
Intravenous Acyclovir Dosing
Indications for IV Therapy
Intravenous acyclovir is indicated for immunocompromised patients with varicella and has demonstrated effectiveness in reducing morbidity and mortality when administered within 24 hours of rash onset 2. IV therapy should also be considered for severe complications such as pneumonitis in pregnant women 5.
IV Dosing Regimens
- Standard dose: 10 mg/kg IV every 8 hours 6, 7
- Alternative dosing: 500 mg/m² IV every 8 hours 7
- Duration: Typically 7-10 days for immunocompromised patients 7
Recent pharmacokinetic data suggests higher dosing may be needed in certain populations: For children with normal renal function (eGFR ≤250 mL/min/1.73 m²), 10 mg/kg every 6 hours is appropriate. For children with augmented renal clearance (eGFR >250 mL/min/1.73 m²), consider 15-20 mg/kg every 6 hours 8.
Renal Adjustments for IV Therapy
Dosing must be adjusted based on creatinine clearance. In severe renal failure (anuric patients), the half-life extends from 2.5 hours to 19.5 hours, requiring substantial dose reduction 6.
Who Should Receive Treatment
Recommended Treatment Groups
According to AAP and ACIP guidelines, oral acyclovir should be considered for otherwise healthy persons at increased risk for moderate to severe varicella 2:
- Persons aged >12 years (disease is more severe in adolescents and adults) 3, 4
- Persons with chronic cutaneous or pulmonary disorders
- Persons receiving long-term salicylate therapy
- Persons receiving short, intermittent, or aerosolized corticosteroids
- Secondary household contacts (some experts recommend)
- Pregnant women with severe complications (IV acyclovir for pneumonitis) 5
NOT Routinely Recommended
Acyclovir is NOT routinely recommended for otherwise healthy children because the clinical benefit was insufficient to justify routine administration in this population 2. While studies showed modest reductions in symptoms, complications occurred in only 1-2% of cases, making it difficult to demonstrate significant impact on disease severity.
Critical Caveats and Pitfalls
Timing is everything: The 24-hour window from rash onset is crucial. Treatment initiated after this period has dramatically reduced efficacy 2, 3, 4. One study showed that treatment within the first 24 hours produced dramatic reduction in rash and clinical illness, while later treatment had minimal benefit 4.
Hydration requirements: At the higher doses used for varicella (800 mg orally or 10 mg/kg IV), adequate hydration and urine flow must be maintained to prevent crystalluria 7.
Monitor mental status: Neurological side effects can occur, particularly in patients with renal impairment 7.
Pregnancy considerations: Acyclovir is FDA Category B. While not routinely recommended for uncomplicated varicella in pregnancy, IV acyclovir (10-15 mg/kg or 500 mg/m² every 8 hours for 5-10 days) should be considered for serious complications like pneumonitis, ideally started within 24-72 hours of rash onset 5.
Not for prophylaxis: Acyclovir is not indicated for prophylactic use in otherwise healthy individuals after varicella exposure—vaccination is preferred 2.